This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

10 Small-Cap Stocks Poised to Rise, History Shows (Update2)

10. Zoll Medical (ZOLL)

Company profile: Zoll, with a market value of $2 billion, makes medical equipment used to resuscitate victims of trauma or cardiac arrest.

Investor takeaway: Its shares are up 19% this year and 53% over the past three months, and have a three-year, average annual return of 88%.

Analysts give its shares four "buy" ratings, three "buy/holds," and one "hold," according to a survey of analysts by S&P.

Revenue has risen steadily over the past five years and, earnings, over three years. For fiscal 2012, analysts estimate Zoll Medical will earn $1.95 per share and that will grow by 36% to $2.65 in 2013.

9. Ista Pharmaceuticals (ISTA)

Company profile: Ista Pharmaceuticals, with a market value of $355 million, develops various drugs for the ophthalmic market. It is also working on allergy drugs.

Investor takeaway: Ista's shares are up 21% this year, including 116% in the past three months, and have a three-year, average annual return of 69%.

Analysts give the stock one "buy/hold" rating and three "holds," per S&P. For fiscal 2012, analysts estimate earnings will grow 312% to 33 cents per share. For 2011, the company reported a net loss of $57 million or $1.47 per share, but it had operating income of $2.28 per share.

8. Buffalo Wild Wings (BWLD - Get Report)

Company profile: Buffalo Wild Wings, with a market value of $1.6 billion, is a casual dining restaurant chain that owns and franchises 560 restaurants in 38 states.

Investor takeaway: Buffalo Wild Wings' shares are up 32% this year, 42% over the past three months, and have a three-year, average annual return of 43%.

Analysts give them seven "buy" ratings, one "buy/holds," nine "holds," and one "sell," according to S&P. Analysts estimate it will earn $3.28 per share this year and that that will grow by 17% to $3.85 in 2013. Revenue, earnings and cash flow are up by double-digit amounts over the past five years.

7. Mako Surgical (MAKO)

Company profile: Mako Surgical, with a market value of $1.6 billion, develops a robotic device and implants for a minimally invasive knee procedure called the MAKOplasty.

Investor takeaway: Its shares are up 41% over the past three months and have a three-year average annual return of 77%. Analysts give them one "buy" rating, two "buy/holds," and five "holds," according to S&P.

6. Bio-Reference Labs (BRLI - Get Report)

Company profile: Bio-Reference Labs, with a market value of $642 million, is a New Jersey-based company that performs chemical-diagnostic tests, including blood and urine analysis, hematology services, pap smears and other types of tests.

Investor takeaway: Its shares are up 42% this year, including 65% in the past three months, and have a three-year, average annual return of 29%. Analysts give the stock three "buy" ratings and two "holds," according to a survey of analysts by S&P.

Bio-Reference Labs expected to earn $1.45 per share this year, and that that will grow by 19% to $1.73 per share in 2013. The company has five years of steady revenue, earnings and cash flow growth.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BRLI $35.15 -0.06%
BWLD $183.29 0.53%
CRUS $33.10 -0.57%
EZCH $19.48 0.41%
AAPL $125.30 1.70%

Markets

DOW 17,976.38 +263.72 1.49%
S&P 500 2,082.20 +21.18 1.03%
NASDAQ 4,934.3160 +43.0970 0.88%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs